EMA Authorised: Bomyntra (denosumab) — Fresenius Kabi Deutschland GmbH

View source ↗

Summary

The European Medicines Agency authorised Bomyntra (denosumab) by Fresenius Kabi Deutschland GmbH for neoplasms of bone tissue, including giant cell tumor of bon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Tumor of Bone

Drugs mentioned

• Bomyntra (denosumab)

Snippet

Status: Authorised. Therapeutic area: Neoplasms, Bone Tissue;Giant Cell Tumor of Bone. MAH: Fresenius Kabi Deutschland GmbH. Decision date: 17/07/2025